Lv11
20 积分 2021-11-29 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7小时前
待确认
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
7小时前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
7小时前
已关闭
Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease
2个月前
已完结
Translational PK–PD for targeted protein degradation
5个月前
已完结
New immune cell engagers for cancer immunotherapy
5个月前
已完结
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
5个月前
已完结
RNA regulation of inflammatory responses in glia and its potential as a therapeutic target in central nervous system disorders
6个月前
已完结
The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
6个月前
已完结
Glioma
11个月前
已完结
TotalSegmentator: robust segmentation of 104 anatomical structures in CT images
2年前
已采纳
Development and validation of a prognostic nomogram for myocardial infarction patients in intensive care units: a retrospective cohort study
2年前
已采纳
皖公网安备34019202002308
